Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Microbiome of the Eye01:22

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors predicting tolerance of egg allergy.

The journal of allergy and clinical immunology. Global·2026
Same author

An updated review for management of atopic dermatitis.

Asian Pacific journal of allergy and immunology·2026
Same author

Wheat allergy, a new and emerging threat of food allergy for children.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.

Allergy·2025
Same author

Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024-2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms.

Allergy·2025
Same author

Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GA<sup>2</sup>LEN and EFA consensus statement.

Clinical and translational allergy·2025

Related Experiment Video

Updated: May 8, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Immunomodulators for conjunctivitis.

Punchama Pacharn1, Pakit Vichyanond

  • 1Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Current Opinion in Allergy and Clinical Immunology
|August 27, 2013
PubMed
Summary
This summary is machine-generated.

Newer treatments for allergic conjunctivitis offer improved outcomes, especially for severe cases. These therapies target inflammatory pathways beyond histamine, providing sustained relief for allergic eye conditions.

More Related Videos

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva
07:35

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

Published on: July 5, 2017

Related Experiment Videos

Last Updated: May 8, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva
07:35

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

Published on: July 5, 2017

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Allergic conjunctivitis is an IgE-mediated inflammatory condition of the conjunctiva.
  • Histamine is a primary mediator, but topical antihistamines offer only temporary relief.
  • Agents targeting inflammatory cascades are needed for prolonged and severe allergic conjunctivitis.

Purpose of the Study:

  • To review new therapeutic agents for allergic conjunctivitis.
  • To examine the mechanisms of action and clinical efficacy of these treatments.
  • To focus on immunomodulatory options for severe cases.

Main Methods:

  • Review of scientific literature on allergic conjunctivitis treatments.
  • Analysis of second-generation antihistamines with anti-inflammatory properties.
  • Examination of other therapies including corticosteroids, immunotherapy, and immunomodulators.

Main Results:

  • Second-generation antihistamines (ketotifen, epinastine, olopatadine) show anti-inflammatory effects.
  • Cromolyn, nedocromil, topical corticosteroids, and immunotherapy are also discussed.
  • Cyclosporine A and tacrolimus show promising results in severe conjunctivitis.

Conclusions:

  • Several immunomodulatory options are available for allergic conjunctivitis treatment.
  • These therapies improve outcomes, particularly for patients with severe disease.
  • Newer agents offer better management for the spectrum of allergic conjunctivitis.